GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroBo Pharmaceuticals Inc (NAS:NRBO) » Definitions » Cyclically Adjusted PB Ratio

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.02 (As of May. 26, 2024)


View and export this data going back to 2016. Start your Free Trial

What is NeuroBo Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-26), NeuroBo Pharmaceuticals's current share price is $4.13. NeuroBo Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 was $262.02. NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.02.

The historical rank and industry rank for NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

NRBO' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.02
Current: 0.02

During the past 10 years, NeuroBo Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.02. The lowest was 0.00. And the median was 0.00.

NRBO's Cyclically Adjusted PB Ratio is ranked better than
97.09% of 653 companies
in the Biotechnology industry
Industry Median: 1.73 vs NRBO: 0.02

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

NeuroBo Pharmaceuticals's adjusted book value per share data of for the fiscal year that ended in Dec23 was $3.401. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $262.02 for the trailing ten years ended in Dec23.

Shiller PE for Stocks: The True Measure of Stock Valuation


NeuroBo Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroBo Pharmaceuticals Cyclically Adjusted PB Ratio Chart

NeuroBo Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.01

NeuroBo Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.01 -

Competitive Comparison of NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



NeuroBo Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=4.13/262.02
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeuroBo Pharmaceuticals's Cyclically Adjusted Book per Share for the fiscal year that ended in Dec23 is calculated as:

For example, NeuroBo Pharmaceuticals's adjusted Book Value per Share data for the fiscal year that ended in Dec23 was:

Adj_Book=Book Value per Share/CPI of Dec23 (Change)*Current CPI (Dec23)
=3.401/129.4194*129.4194
=3.401

Current CPI (Dec23) = 129.4194.

NeuroBo Pharmaceuticals Annual Data

Book Value per Share CPI Adj_Book
201412 -265.500 99.070 -346.835
201512 -8,091.503 99.792 -10,493.760
201612 13,397.403 101.863 17,021.774
201712 2,226.554 104.011 2,770.467
201812 -5,582.353 105.998 -6,815.840
201912 189.195 108.420 225.839
202012 87.884 109.897 103.496
202112 131.398 117.630 144.568
202212 6.841 125.222 7.070
202312 3.401 129.419 3.401

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


NeuroBo Pharmaceuticals  (NAS:NRBO) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


NeuroBo Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of NeuroBo Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
200 Berkeley Street, Office 19th Floor, Boston, MA, USA, 02116
NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused primarily on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of nonalcoholic steatohepatitis (NASH), obesity, and type 2 diabetes (T2D): DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
Executives
James Patrick Tursi director 106 ASHLEY COURT, MOORESTOWN NJ 08057
Marshall H Woodworth officer: Acting Chief Financial Officer C/O NEUROBO PHARMACEUTICALS, INC., 545 CONCORD AVENUE, SUITE 210, CAMBRIDGE MA 02138
Mark A Glickman director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Joseph Hooker officer: Interim CEO and President C/O NEUROBO PHARMACEUTICALS, INC., 200 BERKELEY ST, OFFICE 19TH FLOOR, BOSTON MA 02116
Goldman Sachs Group Inc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
Goldman Sachs & Co. Llc 10 percent owner 200 WEST STREET, NEW YORK NY 10282
E&healthcare Investment Fund Ii 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 06211
E&investment, Inc. 10 percent owner 16TH FLOOR, YEOKSAM I-TOWER, B/D 326, TEHERAN-RO, GANGNAM-GU, SEOUL M5 00000
Hyung Heon Kim director C/O DONG-A ST & DONG-A SOCIO GROUP, 64 CHEONHO DAERO, DONGDAEMUN-GU, SEOUL M5 00000
Andrew I Koven director 3 COLUMBUS CIRCLE, SUITE 1710, C/O ARALEZ PHARMACEUTICALS INC., NEW YORK NY 10019
Na Yeon Kim director, 10 percent owner C/O NEUROBO PHARMACEUTICALS, INC., 177 HUNTINGTON AVENUE, SUITE 1700, BOSTON MA 02115
Richard Kang director 9451 SUNNYFIELD COURT, POTOMAC MD 20854
D Gordon Strickland director C/O AMPEX CORPORATION, 1228 DOUGLAS AVENUE, REDWOOD CITY CA 94063
Ben Gil Price officer: CEO and President 8297 CHAMPIONS GATE BLVD. #444, CHAMPIONS GATE FL 33896
Akash Bakshi director, officer: SVP and COO 602 BAINBRIDGE STREET, FOSTER CITY CA 94404

NeuroBo Pharmaceuticals (NeuroBo Pharmaceuticals) Headlines

From GuruFocus